Trial Profile
A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Tafasitamab (Primary) ; Bendamustine; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms B-MIND
- Sponsors MorphoSys
- 03 Dec 2022 This trial has been completed in Austria according to European Clinical Trials Database record.
- 01 Aug 2022 Planned End Date changed from 1 Mar 2024 to 1 Jun 2024.
- 01 Aug 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Jun 2024.